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A B S T R A C T
Objectives: To investigate the effect of human T-lymphotropic virus type 1 (HTLV-1) on CD4 counts and
mortality in tuberculosis (TB) patients with or without human immunodeﬁciency virus (HIV).
Methods: A prospective study on 280 hospitalized patients with pulmonary TB was performed in
Guinea-Bissau, 1994–1997, including HIV, CD4 counts and clinical outcome. We compared the CD4
count levels at the time of inclusion between HIV-negative and HIV-positive patients, with or without
HTLV-1. Mortality was determined while patients were on treatment for TB.
Results: Median CD4% was signiﬁcantly higher in HIV-positive subjects co-infected with HTLV-1
compared to HTLV-1-negative patients. Two hundred thirty-three individuals were included in the
analysis of mortality, and among HIV-negative subjects the mortality was 18.6/100 person-years . In
HIV-2-positive HTLV-1-negative subjects themortality was 39.5/100 person-years and in HIV-2/HTLV-1
co-infected patients it was 113.6/100 person-years (adjusted mortality rate ratio 4.7, 95% CI 1.5–14.4; p
< 0.01). When all HIV-positive patients were analyzed together, corresponding mortality rates were
53.5/100 person-years and 104.8/100 person-years , respectively (not signiﬁcant).
Conclusions: HIV/HTLV-1 co-infected patients hospitalized for pulmonary TB had a high mortality and
had signiﬁcantly higher CD4% compared to only HIV-positive subjects. This may imply that HTLV-1 has
an adverse effect on the immune system in HIV-infected subjects, independently of the CD4 count, that
makes co-infected subjects more vulnerable to TB.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The deleterious effects of the human immunodeﬁciency virus
(HIV) andMycobacterium tuberculosis infections (MTB) worldwide,
and especially in developing countries, are well-known. Further-
more, HIV-infected subjects are more susceptible to MTB, and
tuberculosis (TB) is the most common cause of death in HIV-
positive adults living in developing countries.1 The ﬁrst isolated
human retrovirus was human T-lymphotropic virus type 1 (HTLV-
1), and it is spread endemically in sub-Saharan Africa, Japan, South
America and the Caribbean.2 HTLV-1 infection has been associated
with a wide range of diseases, including adult T-cell leukemia/
lymphoma (ATL), HTLV-1 associated myelopathy/tropical spastic
paraparesis (HAM/TSP), uveitis, and autoimmune manifestations,* Corresponding author. Tel.: +46 46 171130; fax: +46 46 323895.
E-mail address: Hans.Norrgren@med.lu.se (H. Norrgren).
1201-9712/$36.00 – see front matter  2010 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.11.040as well as infection with Strongyloides stercoralis.3 It has also been
shown that HTLV-1-positive asymptomatic subjects have a
suppressed Mantoux test (PPD, puriﬁed protein derivative test)
compared to HTLV-1-negative controls.4–6
Several studies of co-infection of HIV-1 andHTLV-1 have shown
increased CD4 count levels compared to HIV-1mono-infection.7–11
However, in one study no association was found between co-
infection of HIV/HTLV-1 and higher CD4 counts.12 In some reports,
the progression to AIDS or death has been found to be faster in HIV-
1/HTLV-1 co-infection compared to HIV-1-positive HTLV-1-nega-
tive subjects,11,13 while in one study no difference was demon-
strated.10
The association betweenHTLV-1 and TB has been examined in a
few studies with contradicting results.14 We have recently
published a paper from a prospective TB study conducted in
Guinea-Bissau on hospitalized patientswith pulmonary TB, andwe
could not ﬁnd any association between HTLV-1 infection and TB in
HIV-negative patients, but in HIV-positive patients there was ases. Published by Elsevier Ltd. All rights reserved.
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knowledge only one study has previously investigated the
outcome of TB in HTLV-1-infected patients, and the results
indicated a highermortality in HTLV-1-infected patients compared
to HTLV-1-negative subjects, although no statistical analysis was
performed.16
Guinea-Bissau has the highest prevalence of HIV-2 in theworld,
and in recent years HIV-1 has increased rapidly and the prevalence
is now approximately 5% among pregnant women in the capital
Bissau.17 HTLV-1 is endemic in the country and the prevalence was
reported to be 3.6% in a population-based study from Bissau in
2000.18 In the same study population the incidence of TB was 471
per 100 000 person-years, among the highest noted in the world.19
Following our above-mentioned prospective study of TB
patients in Guinea-Bissau, we have now investigated the mortality
while patients were on treatment for TB and have related it to
immunological parameters and HIV/HTLV-1 status. The results of
this study were presented in part at the 14th International
Conference on Human Retrovirology, July 2009.20
2. Materials and methods
Patients hospitalized for pulmonary TB at the Raoul Follereau
Hospital in Bissau between 1994 and 1997 were consecutively
screened, and adults (aged 15 years) living in Bissau with no
previous history of TB were enrolled. The diagnosis of pulmonary
TB was culture-conﬁrmed in 145 cases, and in 135 subjects the
diagnosis was based on a smear-positive sputum sample or on
clinical and radiological criteria (inﬁltrative, nodular, or cavitary
lesions). After informed consent was obtained from the patient, a
blood sample was drawn for the analyses of HIV and T-lymphocyte
subsets. Subsequently the frozen blood sample was also analyzed
for antibodies to HTLV-1/2. A PPD test was done intradermally (2
TU) and was considered positive when the induration diameter
was >5 mm. Standard national treatment regimens were used,
which for HIV-negative patients at that time included 2 months of
streptomycin, rifampin, isoniazid and pyrazinamide, followed by 6
months of isoniazid and thioacetazone. HIV-positive patients
initially received 4 months of rifampin, isoniazid, pyrazinamide
and ethambutol, and then 4 months of isoniazid and thioaceta-
zone. However, during the study period treatment guidelines were
changed for HIV-positive patients from isoniazid and thioaceta-
zone during the continuation phase to isoniazid and ethambutol.
Some of the HIV-positive patients also received rifampin during
the continuation phase. This treatment regimen was used at that
time in several African countries due to lower costs, but since then
newer treatment regimens have been adopted. The study period
included the whole treatment period of 8 months. Patients were
hospitalized for approximately 2 months, and during this phase
daily visits were undertaken to the wards in order to follow the
clinical outcome in the participants. During the ambulatory phase
of the treatment, participants were visited every month in the
home by a specially appointed nurse, and at the end of the
treatment period a ﬁnal evaluation was done by a doctor.Table 1
Prevalence of HTLV-1 (%) among 280 hospitalized patients with pulmonary tuberculos
HIV-negative HIV-1
N 162 26
Male 3/104 (2.9) 1/17 (5.9)
Female 3/58 (5.2) 2/9 (22.2)
Total 6/162 (3.7) 3/26 (11.5)
HTLV, human T-lymphotropic virus; HIV, human immunodeﬁciency virus.
a p < 0.05, Chi-square test for paired comparison between the indicated HIV-positiv
b p < 0.001, Chi-square test for paired comparison between the indicated HIV-positi
c p < 0.05, Chi-square test for paired comparison between HIV-positive men and woTreatment failure was deﬁned as persisting symptoms of TB and
sputum smear positivity at the end of the study period. Due to the
outbreak of a civil war in Guinea-Bissau in June 1998, a small
subset of individuals (nine HIV-negative individuals) was followed
for only 6 months; however these subjects were considered
clinically cured by the study personnel at this point in therapy. Due
to the unexpected and unreported loss of a study nurse during the
investigation, the follow-up was interrupted in 47 patients, hence
these patients were excluded from the follow-up analysis. Thus, a
total of 280 patients were included in the study for the analysis of
immunological parameters, but only 233 subjects were available
for the mortality analysis. No antiretroviral treatment was given
since it was not available in the country at the timewhen the study
was conducted.
All sera were screened by the Enzygnost HIV-1+2 ELISA
(Behring, Marburg, Germany). Conﬁrmation was carried out
according to an alternative conﬁrmatory strategy including two
separate HIV-1 and HIV-2 ELISAs, Enzygnost anti-HIV-1 and
Enzygnost anti-HIV-2 (Behring), and a rapid simple assay,
Recombigen HIV-1/HIV-2 RTD (Cambridge Biotech Ltd, Galway,
Ireland).21 Sera dually reactive for HIV-1 and HIV-2 were further
tested by Peptilav 1–2 (Sanoﬁ Diagnostics Pasteur, Marnes-la-
Coquette, France).
Detection of antibodies to HTLV-1/2 was achieved using the
Organon Vironostika HTLV-1 (Organon Teknika BV, Boxtel, the
Netherlands) and the Murex HTLV-1/2 GE80/81 (Murex Diag-
nostics Ltd, Dartford, UK) tests. Positive reactions were conﬁrmed
by Western blot (WB) – the Diagnostic Biotechnology HTLV-blot
2.3 (Genelabs Diagnostics, Singapore). The criteria for HTLV
seropositivity were reactivity with at least one core band and at
least two envelope bands. The recombinant gp46-I and gp46-II
bands were used to differentiate between HTLV-1 and HTLV-2. T-
lymphocyte subsets were determined at the National Public
Health Laboratory (LNSP) in Bissau by ﬂow cytometry (FACStrak,
Becton Dickinson, San Jose, CA, USA) using three two-color
immunoﬂuorescence reagents: CD45/CD14, CD3/CD4 and CD3/
CD8 (Simultest, BectonDickinson). Leukocyteswere countedwith
a Coulter Counter CBC 5 (Coulter Electronics Ltd, Luton, UK).
Sputum microscopy and TB culture were performed according to
standard methods at the National Public Health Laboratory, as
previously described.22
2.1. Statistical analysis
Odds ratios (OR) with 95% conﬁdence intervals (CI), p-values of
Chi-square tests, Fisher’s exact test and the Mann–Whitney test
were calculated with Epi Info (Centers for Disease Control and
Prevention (CDC), Atlanta, GA, USA andWorldHealth Organization,
Geneva, Switzerland). Many datawere not normally distributed, so
the central tendency and dispersion are given by median and P25
and P75 interquartile ranges (IQR). For the analysis of mortality,
subjects who discontinued treatment or who were lost to follow-
up contributed with person-years until their last control (taking
therapy). Multivariate logistic regression analyses were performedis, stratiﬁed by HIV status and gender
HIV-2 HIV-1 + HIV-2 HIV-positive
60 32 118
5/31 (16.1)a 3/16 (18.8)a 9/64 (14.1)a
7/29 (24.1)a 8/16 (50)b 17/54 (31.5)b,c
12/60 (20)b 11/32 (34.4)b 26/118 (22.0)b
e groups and the HIV-negative subjects.
ve groups and the HIV-negative subjects.
men.
Table 2
Median values (interquartile ranges in parentheses) of lymphocyte subsets and number of subjects (percentages in parentheses) of subjects with negative PPD and negative
sputum culture of Mycobacterium tuberculosis among 280 hospitalized patients with pulmonary tuberculosis, stratiﬁed by HIV and HTLV-1 status
HTLV-1 HIV-negative HIV-1 HIV-2 HIV-1 + HIV-2 HIV-positive
N Negative 156 23 48 21 92
Positive 6 3 12 11 26
CD4% Negative 40 (33–46) 11 (9–17) 13 (7–28) 15 (5–25) 13 (7–26)
Positive 40 (33–42) 21 (6–40) 22 (13–35) 23 (13–37) 22 (13–37)b
Total CD4a Negative 666 (487–919) 162 (80–215) 243 (60–391) 182 (107–389) 177 (75–389)
Positive 695 (496–1085) 838 (341–1296)c 247 (123–594) 204 (116–541) 284 (129–594)
CD8% Negative 27 (22–35) 56 (49–68) 44 (36–60) 53 (47–62) 51 (39–64)
Positive 31 (28–32) 48 (48–58) 47 (29–57) 49 (40–60) 48 (39–60)
Total CD8a Negative 506 (347–655) 704 (435–1481) 550 (279–1079) 661 (333–1076) 652 (337–1184)
Positive 516 (448–657) 1915 (1555–3293)c 470 (454–638) 699 (358–984) 638 (462–983)
Negative PPD Negative 44/124 (35.5) 12/20 (60) 19/33 (57.6)d 6/13 (46.2) 37/66 (56.1)e
Positive 2/6 (33.3) 1/2 (50) 4/11 (36.4) 7/11 (63.6) 12/24 (50)
Negative TB culture Negative 54/137 (39.4) 11/21 (52.4) 16/45 (35.6) 11/19 (57.9) 38/85 (44.7)
Positive 0/5 0/2 6/10 (60) 6/10 (60) 12/22 (54.5)
PPD, puriﬁed protein derivative (Mantoux) test; HTLV, human T-lymphotropic virus; HIV, human immunodeﬁciency virus.
a The number of analyzed HTLV-1-negative andHTLV-1-positive subjects was 151, 22, 45, and 19, and 6, 3, 11, and 11, respectively, in HIV-negative, HIV-1-positive, HIV-2-
positive, and HIV-1 + HIV-2-positive subjects, respectively .
b p < 0.05, Mann–Whitney test for paired comparison of HIV-positive HTLV-1-negative and HTLV-1-positive subjects.
c p < 0.05, Mann–Whitney test for paired comparison of HIV-1-positive HTLV-1-negative and HTLV-1-positive subjects.
d p < 0.05, Mann–Whitney test for paired comparison of HIV-2-positive and HIV-negative HTLV-1-negative subjects.
e p < 0.05, Mann–Whitney test for paired comparison of HIV-positive and HIV-negative HTLV-1-negative subjects.
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variable in the regression analyses.
3. Results
Among the 280 study subjects, the total prevalence of HIV-1
was 9.3%, of HIV-2was 21.4%, and of HIV-1 +HIV-2was 11.4%. The
prevalence ofHTLV-1 according toHIV status and gender is shown
in Table 1. No patient was found to be HTLV-2-positive. The
prevalence of HTLV-1 was signiﬁcantly higher in HIV-2, HIV-1 +
HIV-2, and in all HIV-positive patients combined as compared to
HIV-negative subjects. Therewas a trend towards a higherHTLV-1
prevalence among women compared to men in all groups, which
became signiﬁcant when all HIV-positive patients were analyzed
together. Themedian age ofHIV-negative subjectswas30years, of
HIV-1 subjects was 30.5 years, of HIV-2 subjects was 42.5 years,
and of HIV-1 + HIV-2-positive subjects was 40 years. No
signiﬁcant differences in median age were noted between
HTLV-1-positive and HTLV-1-negative patients in the HIV-2
and HIV-1 + HIV-2-positive groups, but in the HIV-negative and
HIV-1-positive groups median age was signiﬁcantly higher in
HTLV-1-positive subjects compared to HTLV-1-negative indivi-
duals (data not shown).Table 3
Outcome of treatment in 233 patients with pulmonary tuberculosis (percentages in pa
HTLV-1 Treatment
discontinued
Loss to
follow-up
HIV-negative Negative 7 (5.6) 20 (15.9)
Positive 0 1 (25)
HIV-1 Negative 0 4 (20)
Positive 1 (33.3) 0
HIV-2 Negative 3 (6.8) 2 (4.5)
Positive 0 0
HIV1 + HIV-2 Negative 1 (5.3) 4 (21.1)
Positive 0 3 (30)
HIV-positive Negative 4 (4.8) 10 (12.0)
Positive 1 (5) 3 (15)
HTLV, human T-lymphotropic virus; HIV, human immunodeﬁciency virus.
a Nine HIV-negative individuals were followed for only 6 months, but were conside
b p < 0.05, Chi-square test for paired comparison between the indicated HIV-positiv
c p < 0.01, Chi-square test for paired comparison between the indicated HIV-positiv
d p < 0.001, Chi-square test for paired comparison between the indicated HIV-positIn Table 2 we present the immunological differences between
HTLV-1-negative and HTLV-1-positive patients according to HIV
status. The proportions of subjects with a negative PPD and
negative culture of TB are also shown for each group. No difference
could be found in any of the immunological parameters between
HTLV-1-negative and HTLV-1-positive patients in the HIV-nega-
tive group, but in the three different HIV-positive groups therewas
a trend towards higher CD4% among the HTLV-1-positive subjects
(although not signiﬁcant). However, when all HIV-positive
subjects were taken together, the difference was signiﬁcant, which
was also veriﬁed in a logistic regression analysis adjusting for age
and gender (p = 0.01; 95% CI 1.9–13.6). Regarding total CD4 counts
the pattern was similar, but here the difference was signiﬁcant
only in the HIV-1- positive group (p< 0.05).When looking at CD8%
and total CD8 counts, similar values were found in HTLV-1-
negative and HTLV-1-positive patients regardless of HIV status,
with the exception of total CD8 counts in HIV-1-positive subjects.
However, this was due to high lymphocyte counts in the three
individuals in this group (data not shown), which also explains the
surprisingly high total CD4 counts in this group. As could have
been expected, signiﬁcantly more HIV-positive patients had a
negative PPD compared to HIV-negative subjects (HTLV-1-
negative individuals only), but no signiﬁcant differences wererentheses), stratiﬁed by HIV and HTLV-1
Case-fatality
during treatment
Treatment failure
after 8 months
of treatment
Clinical cure after
8 months of treatmenta
15 (11.9) 7 (5.6) 77 (61.0)
0 0 3 (75)
8 (40)c 2 (10) 6 (30)b
1 (33.3) 0 1 (33.3)
12 (27.3)b 6 (13.6) 21 (47.8)
5 (71.4) 0 2 (28.6)
7 (36.7)b 3 (15.8) 4 (21.1)c
5 (50) 1 (10) 1 (10)
27 (32.5)d 11 (13.3) 31 (37.4)d
11 (55) 1 (5) 4 (20)
red clinically cured by the study personnel at this point in therapy.
e groups and the corresponding HIV-negative group.
e groups and the corresponding HIV-negative group.
ive groups and the corresponding HIV-negative group.
Table 4
Mortality rate during treatment of pulmonary tuberculosis among 233 patients, stratiﬁed by HIV and HTLV-1 status
HTLV-1 No. of
subjects
Person-years No. deceased Mortality rate,
n/100 person-years
Mortality rate ratio
(95% CI), p-value
Adjusteda mortality
rate ratio (95% CI), p-value
HIV-negative Negative 126 80.7 15 18.6
Positive 4 2.5 0 0
HIV-1 Negative 20 11.1 8 72.1
Positive 3 1.4 1 71.4 1.1 (0.1–8.9), p = 0.98
HIV-2 Negative 44 30.4 12 39.5
Positive 7 4.4 5 113.6 3.2 (1.1–9.1), p = 0.03 4.7 (1.5–14.4), p = 0.008
HIV-1 + HIV-2 Negative 19 9.0 7 77.8
Positive 10 4.7 5 106.4 1.3 (0.4–4.1), p = 0.65
HIV-positive Negative 83 50.5 27 53.5
Positive 20 10.5 11 104.8 2.0 (1.0–4.0), p = 0.06 1.7 (0.9–3.6), p = 0.13
HTLV, human T-lymphotropic virus; HIV, human immunodeﬁciency virus; CI, conﬁdence interval.
a Adjusted for age and gender.
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in any group. Nor could we see any differences between men and
women with regard to PPD reactivity in relation to HTLV status
(data not shown). A trend towards higher proportions of negative
TB cultures could be observed in HIV-positive subjects, but no
signiﬁcant differences were found.
For the analysis of clinical outcome, 233 individuals were
available for an evaluation (Table 3). No signiﬁcant differences
were found regarding treatment discontinuation, loss to follow-up,
or treatment failure at the end of the treatment period. However,
the case-fatality was higher in all HIV-positive groups compared to
HIV-negative subjects (only HTLV-1 negative patients); the
mortality rates are shown in Table 4. Overall, HIV-positive
patients had several times higher mortality compared to HIV-
negative subjects. In HIV-negative subjects no HTLV-1-positive
patient died (although there were few patients in this group), and
in HIV-1-positive patients the same mortality was found in HTLV-
1-negative and HTLV-1-positive subjects. However, the highest
mortality was found in HIV-2-positive and HTLV-1-positive
individuals (113.6/100 person-years), which was signiﬁcantly
higher compared to HIV-2-positive and HTLV-1-negative patients
(mortality rate ratio 3.2; p < 0.05). The mortality rate ratio further
increased to 4.7 (95% CI 1.5–14.4; p< 0.01) when adjusting for age
and gender in a logistic regression analysis. In HIV-1 + HIV-2-
positive subjects there was a trend towards higher mortality in
HTLV-1-positive patients, although not signiﬁcant. When all HIV-
positive patients were analyzed together the adjusted mortality
rate ratio between HTLV-1-positive and negative subjects was 1.7
(95% CI 0.9–3.6; p = 0.13).
We further investigated if HTLV-1 had a different impact on the
mortality at the different stages of immunosuppression in HIV-
positivesubjects. InTable 5weshowthemortality inallHIV-positive
subjects taken together (since they were too few to be divided intoTable 5
Mortality rate during treatment of pulmonary tuberculosis among 103 HIV-positive pa
HTLV-1 No. of subjects Person-years
CD4% 14 Negative 45 21.6
Positive 7 2.1
CD4% 15–24 Negative 13 9.6
Positive 6 3.6
CD4% 25 Negative 25 19.3
Positive 7 4.8
Total CD4 <200 Negative 42 20.3
Positive 8 3.8
Total CD4 200–349 Negative 12 9.3
Positive 4 2.0
Total CD4 350 Negative 24 18.4
Positive 7 4.6
HTLV, human T-lymphotropic virus; HIV, human immunodeﬁciency virus; CI, conﬁdeneach HIV-positive group) according to CD4 counts and HTLV-1
status. Interestingly, HTLV-positive patients had a trend towards
higher mortality at all CD4 count levels, reaching signiﬁcance in
subjects with CD4%25 or a total CD4 count between 200 and 349.
4. Discussion
In the present study of hospitalized patients with pulmonary TB
we found that HIV-positive patients with concomitant HTLV-1
infection had signiﬁcantly higher CD4% than HIV-positive patients
without HTLV-1. When performing separate analyses of HTLV-1-
positive patients co-infected with either HIV-1, HIV-2, or HIV-1 +
HIV-2, a trend towards higher CD4%was found in all groups of HIV,
but the number of patients in the different groups was not
sufﬁcient for conclusive analyses. In spite of this we noted a trend
towards higher mortality in HIV/HTLV-1 co-infected patients as
compared to HIVmono-infected subjects, and in HIV-2/HTLV-1 co-
infected patients the difference became signiﬁcant compared to
HIV-2 singly infected individuals.
The ﬁnding of higher CD4 counts in HIV-1/HTLV-1 co-infected
patients has been observed in other studies.7–11 Regarding HIV-
negative patients, we could not detect any difference in CD4 counts
between HTLV-1-positive and HTLV-1-negative subjects. The
reasons for this discrepancy of CD4 development associated with
HTLV-1, depending on concomitant HIV or not, are not clear. It has
been speculated that the higher CD4 counts in co-infected subjects
could represent HTLV-1-associated non-speciﬁc lymphocyte pro-
liferation.8 Detailed analyses of increased turnover and peripheral
expansion mechanisms during concomitant HTLV and HIV
infection are needed in order to further elucidate this.
Previous studies have demonstrated a weaker reaction to PPD in
HTLV-1-positive subjects compared toHTLV-1-negative controls.4–6
We could not ﬁnd any difference between HTLV-1-positive andtients, stratiﬁed by CD4 counts and HTLV-1 status
No. deceased Mortality rate
n/100 person-years
Mortality rate ratio
(95% CI), p-value
23 106.5
5 238.1 2.2 (0.8–5.7), p = 0.12
2 20.8
2 55.6 2.8 (0.4–20.1), p = 0.31
2 10.4
4 83.3 7.5 (1.4–41.1), p = 0.02
20 98.5
5 131.6 1.3 (0.5–3.4), p = 0.63
1 10.8
3 150.0 12.3 (1.3–119.9), p = 0.03
3 16.3
2 43.5 2.6 (0.4–15.7), p = 0.31
ce interval.
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patients, although signiﬁcantly more HIV-positive subjects had a
negative PPD compared to HIV-negative patients (HTLV-1-negative
individuals only). There were no gender differences in our material,
as has been shown in a previous study.6 However, the previous
observations of negative PPD were found among asymptomatic
healthy subjects, whereas our study cohort consisted of patients
with pulmonary TB, which could affect the results.
We found a signiﬁcantly higher mortality in HIV-2/HTLV-1 co-
infected patients compared to only HIV-2-positive subjects. A
similar trend was found among HIV-1 + HIV-2-positive patients,
but in the HIV-1-positive group no difference was observed.
However, the number of patients in the HIV-1-positive group was
rather limited. At the time when the study was performed, HIV-2
was the dominant type of HIV in Guinea-Bissau, and the prevalence
of HIV-1 was still quite low, which explains the limited number in
this group.23 Moreover, with the relatively short period of HIV-1
prevailing in Guinea-Bissau, the impact on general health would
still be limited at the time of this study. It is likely that many of the
HIV-2-infected patients in our study cohort had had their infection
for a substantially longer time period than the HIV-1-infected
individuals. Thus, any impact of carrying HIV and HTLV-1
concomitantly would probably be more apparent in persons with
a longer period of virus carriage.
In a number of studies, the mortality of HIV-2 has been shown
to be signiﬁcantly lower than that of HIV-1, but higher than among
HIV-negative controls.24–26 Our results indicate that HTLV-1 could
be an important cofactor for HIV-2-relatedmortality in TB patients.
In a study of a rural population in Guinea-Bissau no enhancing
effect of HTLV-1 co-infection onHIV-2mortalitywas found, but the
risk of death increasedwith higher HTLV-1 provirus load.27 Further
studies are needed to explore the inﬂuence of HTLV-1 on HIV-2-
associated morbidity and mortality.
Interestingly, when we compared the mortality according to
different CD4 count levels at the time of diagnosis in HIV-positive
patients,we noted a trend towards highermortality at all CD4 count
intervals among theHTLV-1-positive patients compared toHTLV-1-
negative subjects. Furthermore, the differences were signiﬁcant in
the groupwith CD4%25 and in total CD4 counts between 200 and
349. However, the number of patients, in particular in the HTLV-1-
positive groups,was limited, so the resultsmust be interpretedwith
caution. As could have been expected, the mortality was highest in
the strata with the lowest CD4 counts, both in HTLV-1-positive and
HTLV-1-negative patients (except in HTLV-1-positive patients with
CD4 counts of 200–349), which suggests that CD4 count is the
dominant predictor of clinical outcome; however in all strata it also
appearedas ifHTLV-1hadanadditive inverseeffectonthemortality.
This indicates that the effects of HIV on the immune system cannot
solely be linked to CD4 cell countswhen a person is co-infectedwith
HTLV-1. As compared to HIV single infection, the prognostic value
provided by CD4 cell levels concerning disease progression appears
to be poor. In our study the inﬂuence of HTLV-1 on mortality
appeared tooccur in thehigherCD4cell count strata.Wedonothave
any clear explanation for these somewhat contradictory ﬁndings,
but itmaybethat theeffectsonthe immunesystemcausedbyHTLV-
1 aremore visible in the higher CD4 stratawhere the effect ofHIV on
the clinical outcome is less noticeable.
HTLV-1 has been shown to have proinﬂammatory and carcino-
genic effects, and is also associatedwith several infectious disorders
in HIV-negative individuals.3 In a recently published population-
based study from Guinea-Bissau, an increased mortality was
detected in HIV-negative HTLV-1-positive subjects compared to
HTLV-1-negative individuals.26 In HTLV-1/HIV-1 co-infected sub-
jects a higher mortality compared to HIV-1 mono-infected
individuals has been reported from Brazil,13 but in a study from
Louisiana, USA, no signiﬁcant difference was observed in mortalitybetween HTLV-1/HIV-1 co-infected and HIV-1 mono-infected
subjects.10 To our knowledge only one study has previously
investigated the mortality in patients with TB co-infected with
HIV-1 andHTLV-1, and the results revealed a highermortality in the
co-infected group compared to only HIV-1-infected patients,
although no statistical comparison was performed.16
The biological explanation for a higher mortality in HTLV-1 and
HIV-1 or HIV-2 co-infected TB patients is not obvious, sinceHTLV-1
elicits a strong Th1-type response, which would be expected to
have a suppressive effect on the TB infection as well as the HIV
infections, and rather give an improved outcome.28 It has been
suggested that the negative effect on clinical outcome of HTLV-1 in
HIV-1/HTLV-1 co-infected subjects could be mediated by upregu-
lation of HIV expression due to strong activation of cytokines
promoting HIV replication,29 and this could well be the case in co-
infected patients with TB. Regarding studies of HIV viral load in
HIV/HTLV-1 co-infected subjects, a study from Brazil reported no
signiﬁcant difference in HIV-1 viral load between HIV-1/HTLV-1
co-infected and HIV-1 mono-infected subjects,30 and in a study
from Guinea-Bissau HIV-2/HTLV-1 co-infected subjects had a
signiﬁcantly lower HIV-2 viral load as compared to HIV-2-infected
subjects alone.27 Unfortunately HIV viral load and HTLV-1 proviral
load determinations were not available in the present study. The
scarcity of data on the effects of the co-infections studied here
warrants further studies, but also reﬂects the complexity of studies
of the impact of more than one infection at a time, on each other
and on the host. In an environmentwith a high endemic pressure of
many infectious diseases it is important to take into account the
effects each microorganism will have on the ﬁnal clinical picture.
In conclusion we have observed a highmortality in HIV/HTLV-1
co-infected patients with pulmonary TB, and in HIV-2/HTLV-1-
positive patients the difference was signiﬁcant compared to only
HIV-2-positive subjects. These effects were noted despite sig-
niﬁcantly higher CD4%, which implies that HTLV-1 might have an
adverse effect on the immune system irrespective of CD4 count. It
is of importance that clinicians are aware that HIV/HTLV-1 co-
infected patients can contract TB and perhaps other opportunistic
infections despite high CD4 counts. HTLV-1 may be an important
inducer of HIV-2-associatedmortality in TB patients. Co-infections
with several microorganisms may give unexpected clinical
pictures, difﬁcult to predict based on information from each of
the single infections involved.
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